

# Aspirin Cut CV Risk in Diabetics Over Age 64

BY CAROLINE HELWICK  
Contributing Writer

NEW ORLEANS — Aspirin therapy is commonly used for primary prevention of cardiovascular events in persons with type 2 diabetes, but a Japanese study of 2,539 subjects found no significant reduction in the primary end point of total atherosclerotic events, except in patients aged at least 65 years.

The study, which is the largest primary prevention trial of aspirin in type 2 diabetes, was reported at the annual scientific sessions of the American Heart Association.

In the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, the use of daily low-dose aspirin was associated with a 20% non-significant reduction in the risk of the primary end point (a composite of coronary, cerebrovascular, and peripheral vascular events) in the population as a whole, and a 32% statistically significant reduction in events among those aged 65 and older, reported Dr. Hisao Ogawa of the Kumamoto (Japan) University.

Aspirin use also significantly reduced the composite of fatal coronary and fatal cerebrovascular events.

“Although the effect of low-dose aspirin was not statistically significant for the primary end point, a significant effect was demonstrated on fatal coronary and fatal cerebrovascular events. The trial also suggests that low-dose aspirin might reduce total events in older patients,” he said at a late-breaking trials session.

The results were reported online simultaneously with Dr. Ogawa’s presentation (JAMA 2008;300:2134-41).

Japanese investigators from 163 institutions examined the benefit of low-dose aspirin for preventing cardiovascular events in 2,539 patients with type 2 diabetes who had no history of atherosclerotic disease. Average age of the patients was 65 years, and 55% were men. Patients were randomly assigned to receive 81-100 mg aspirin per day (n = 1,262) or no aspirin (n = 1,277).

After a median follow-up of 4.4 years, a total of 154 fatal and nonfatal atherosclerotic events had occurred: 68 in the aspirin group and 86 in the nonaspirin group. This represented a rate of 13.6 vs. 17.0 events per 1,000 person-years, for a 20% reduction in risk that was not statistically significant, Dr. Ogawa reported.

Among the 719 patients aged at least 65 in the aspirin arm, 45 events (6.3%) atherosclerotic events occurred, compared with 59 events (9.2%) in the 644 older patients in the nonaspirin group, representing a statistically significant 32% reduction in risk with aspirin use.

The combined secondary end point of fatal coronary events and fatal cerebrovascular events occurred in 1 patient (stroke) in the aspirin group and 10 patients (five fatal myocardial infarctions and five fatal strokes) in the nonaspirin group, for a 90% statistically significant reduction in risk for that outcome.

Adverse effects occurred in 86 patients taking aspirin and 14 not on aspirin. Hemorrhagic events were greater with aspirin (34 vs. 10), including an increase in

gastrointestinal bleeding and the need for transfusion for severe GI bleeding in four patients, but there was no increase in hemorrhagic stroke.

“JPAD supports the safety of using low-dose aspirin in diabetics for primary prevention,” he said.

The investigators cautioned that the findings should be interpreted in context of the low incidence of atherosclerotic disease in Japan and the aggressive management of cardiovascular risk factors. “The

event rate was lower than anticipated because the patients were so well treated,” Dr. Ogawa said. “They saw their physicians every 2-4 weeks.”


Dr. Marian Limacher, professor of medicine at the University of Florida, Gainesville, said JPAD was “a well-designed and well-conducted study” that aimed to address a question that “some may have thought did not need to be answered,” given the widespread recommendation for the use of aspirin in dia-

betic patients. “However, the evidence basis for this has been lacking until recently, and JPAD adds to this considerably,” she commented at a press briefing.

The findings are congruent with the recently completed Progression of Arterial Disease and Diabetes (POPADAD) study from the United Kingdom, she noted. POPADAD, involving 1,276 patients with asymptomatic peripheral artery disease, found no evidence for aspirin’s benefit on cardiovascular events and mortality. ■

Relax, we've got  
painful muscle spasm  
under control.

**amrix**<sup>®</sup>  
Cyclobenzaprine HCl  
Extended-Release Capsules



Once-daily **AMRIX**...the proven efficacy of  
cyclobenzaprine with low rates of somnolence.<sup>1</sup>

*AMRIX* (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. *AMRIX* should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. *AMRIX* has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.

*AMRIX* is contraindicated in patients who are hypersensitive to any of its components. *AMRIX* is contraindicated with concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. *AMRIX* may have life-threatening interactions with MAO inhibitors. *AMRIX* is contraindicated during the acute recovery phase of myocardial infarction; in patients with arrhythmias, heart block conduction disturbances, or congestive heart failure; or in patients with hyperthyroidism. *AMRIX* may enhance the effects of alcohol, barbiturates, and other CNS depressants. *AMRIX* should not be used in elderly patients or in patients with impaired hepatic function.

In clinical trials, the most commonly reported adverse reactions (≥3%) with *AMRIX* were dry mouth, dizziness, fatigue, nausea, dyspepsia, and constipation. Please see brief summary of full prescribing information on the following page.

Reference: 1. Data on file. Studies 1105 and 1106. Cephalon, Inc.; 2004.

**Cephalon**  
deliver more.<sup>®</sup>

©2008 Cephalon, Inc. All rights reserved. AMR139 May 2008 Printed in USA.  
*AMRIX* is produced with Eurand Diffucaps<sup>®</sup> technology.

For more information about *AMRIX*, call Cephalon Medical Services at

1-800-896-5855 or visit [www.AMRIX.com](http://www.AMRIX.com)